Loading company…
MiRXES develops diagnostic tests and tools for early detection of cancer and other diseases.
Founded in 2014 and based in Singapore, MiRXES develops diagnostic products, including the GASTROClear blood test for early gastric cancer detection, as well as genomics and infectious disease tools. The company spun off from the Agency of Science, Technology and Research and has offices in China, Hong Kong, Japan, and the US. In July 2023, it raised USD 50 million in Series D funding from Mitsui & Co., Ltd., China Fellow Partners, Agency for Science, Technology and Research, EDBI, and NHH Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in